These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21177375)

  • 1. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
    Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
    Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
    Veitch Z; Zer A; Loong H; Salah S; Masood M; Gupta A; Bradbury PA; Hogg D; Wong A; Kandel R; Charames GS; Abdul Razak AR
    Sci Rep; 2019 May; 9(1):7390. PubMed ID: 31089155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
    Matulonis UA; Lee J; Lasonde B; Tew WP; Yehwalashet A; Matei D; Behbakht K; Grothusen J; Fleming G; Lee NK; Arnott J; Bray MR; Fletcher G; Brokx RD; Castonguay V; Mackay H; Sidor CF; Oza AM
    Eur J Cancer; 2013 Jan; 49(1):121-31. PubMed ID: 22921155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
    Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD
    Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
    Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
    Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
    Du J; Yan L; Torres R; Gong X; Bian H; Marugán C; Boehnke K; Baquero C; Hui YH; Chapman SC; Yang Y; Zeng Y; Bogner SM; Foreman RT; Capen A; Donoho GP; Van Horn RD; Barnard DS; Dempsey JA; Beckmann RP; Marshall MS; Chio LC; Qian Y; Webster YW; Aggarwal A; Chu S; Bhattachar S; Stancato LF; Dowless MS; Iversen PW; Manro JR; Walgren JL; Halstead BW; Dieter MZ; Martinez R; Bhagwat SV; Kreklau EL; Lallena MJ; Ye XS; Patel BKR; Reinhard C; Plowman GD; Barda DA; Henry JR; Buchanan SG; Campbell RM
    Mol Cancer Ther; 2019 Dec; 18(12):2207-2219. PubMed ID: 31530649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
    Lheureux S; Tinker A; Clarke B; Ghatage P; Welch S; Weberpals JI; Dhani NC; Butler MO; Tonkin K; Tan Q; Tan DSP; Brooks K; Ramsahai J; Wang L; Pham NA; Shaw PA; Tsao MS; Garg S; Stockley T; Oza AM
    Clin Cancer Res; 2018 Dec; 24(24):6168-6174. PubMed ID: 30108107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.
    Athwal H; Kochiyanil A; Bhat V; Allan AL; Parsyan A
    Front Oncol; 2024; 14():1370565. PubMed ID: 38606093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The two sides of chromosomal instability: drivers and brakes in cancer.
    Hosea R; Hillary S; Naqvi S; Wu S; Kasim V
    Signal Transduct Target Ther; 2024 Mar; 9(1):75. PubMed ID: 38553459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of Artificial Intelligence and Drug Repositioning for the Identification of Fibroblast Growth Factor Receptor Inhibitors: A Review.
    Zarei P; Ghasemi F
    Adv Biomed Res; 2024; 13():9. PubMed ID: 38525398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AURKA emerges as a vulnerable target for KEAP1-deficient non-small cell lung cancer by activation of asparagine synthesis.
    Deng B; Liu F; Chen N; Li X; Lei J; Chen N; Wu J; Wang X; Lu J; Fang M; Chen A; Zhang Z; He B; Yan M; Zhang Y; Wang Z; Liu Q
    Cell Death Dis; 2024 Mar; 15(3):233. PubMed ID: 38521813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes.
    Banat R; Daoud S; Taha MO
    Mol Divers; 2024 Mar; ():. PubMed ID: 38446372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.
    Nitulescu GM; Stancov G; Seremet OC; Nitulescu G; Mihai DP; Duta-Bratu CG; Barbuceanu SF; Olaru OT
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review.
    Greco S; Fabbri N; Spaggiari R; De Giorgi A; Fabbian F; Giovine A
    Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convenient synthesis, characterization and biological evaluation of novel 1-phenylcyclopropane carboxamide derivatives.
    Mahesh P; Akshinthala P; Ankireddy AR; Katari NK; Gupta LK; Srivastava D; Jonnalagadda SB; Gundla R
    Heliyon; 2023 Feb; 9(2):e13111. PubMed ID: 36747540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora Kinases as Therapeutic Targets in Head and Neck Cancer.
    Nguyen TT; Silva FN; Golemis EA
    Cancer J; 2022 Sep-Oct 01; 28(5):387-400. PubMed ID: 36165728
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.